Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Wealth Enhancement Advisory Services LLC raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 185.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 8,810 shares of the biopharmaceutical company’s stock after buying an additional 5,725 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Intra-Cellular Therapies were worth $645,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Headlands Technologies LLC purchased a new stake in shares of Intra-Cellular Therapies during the 1st quarter valued at about $32,000. Summit Securities Group LLC purchased a new stake in Intra-Cellular Therapies during the second quarter valued at approximately $56,000. CWM LLC lifted its stake in shares of Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 626 shares during the last quarter. EntryPoint Capital LLC lifted its stake in shares of Intra-Cellular Therapies by 138.7% in the 1st quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 1,259 shares during the last quarter. Finally, Cetera Trust Company N.A boosted its holdings in shares of Intra-Cellular Therapies by 24.8% in the 3rd quarter. Cetera Trust Company N.A now owns 2,520 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 500 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Stock Up 1.2 %

Shares of NASDAQ:ITCI opened at $90.51 on Friday. The business’s 50 day moving average is $76.42 and its 200 day moving average is $73.65. The stock has a market cap of $9.60 billion, a P/E ratio of -104.03 and a beta of 0.97. Intra-Cellular Therapies, Inc. has a 52-week low of $52.88 and a 52-week high of $91.68.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same period in the previous year, the company posted ($0.25) EPS. Intra-Cellular Therapies’s quarterly revenue was up 39.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.62 EPS for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 53,013 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Sharon Mates sold 53,013 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares of the company’s stock, valued at $2,229,876. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 175,316 shares of company stock valued at $13,037,345. Company insiders own 2.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ITCI shares. The Goldman Sachs Group decreased their price target on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. UBS Group lowered their target price on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. JPMorgan Chase & Co. increased their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Royal Bank of Canada raised their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.